Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Fudan University
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
69High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06400160CT.gov Clinical Trial of TB511 in Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07412054CT.gov Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC | — | Not Yet Recruiting | — | — | — |
NCT07282509CT.gov Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer | — | Not Yet Recruiting | — | — | — |
NCT07223424CT.gov Patient Preference for Subcutaneous vs. Intravenous Immune Therapy | — | Recruiting | — | — | — |
NCT07106827CT.gov A Study of GV20-0251 in Advanced or Refractory Solid Tumors | — | Recruiting | — | — | — |
NCT07070518CT.gov Study of GV20-0251 in Participants With Solid Tumor Malignancies | — | Recruiting | — | — | — |
NCT06896396CT.gov Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07157969CT.gov ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC | — | Recruiting | — | — | — |
NCT06600321CT.gov A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06422403CT.gov A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers | — | Recruiting | — | — | — |
Show 76 more trialsShow fewer
NCT06389422CT.gov Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis | — | Recruiting | — | — | — |
NCT06205706CT.gov BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04777851CT.gov Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 | — | Terminated | — | — | — |
NCT06022757CT.gov Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) | — | Recruiting | — | — | — |
NCT05824975CT.gov A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | — | Recruiting | — | — | — |
NCT05440708CT.gov A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05708950CT.gov A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | — | Completed | — | — | — |
NCT05286320CT.gov Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. | — | Not Yet Recruiting | — | — | — |
NCT05438420CT.gov Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05208762CT.gov A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05581004CT.gov A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05620134CT.gov Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT05389527CT.gov Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT05185739CT.gov Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) | — | Recruiting | — | — | — |
NCT05256381CT.gov A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05339581CT.gov IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation | — | Unknown | — | — | — |
NCT05101629CT.gov Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy | — | Completed | — | — | — |
NCT05070247CT.gov A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT05269381CT.gov Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05220722CT.gov Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | — | Terminated | — | — | — |
NCT05104567CT.gov A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | — | Completed | — | — | — |
NCT05091346CT.gov A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | — | Completed | — | — | — |
NCT04777708CT.gov BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer | — | Terminated | — | — | — |
NCT05007106CT.gov MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | — | Completed | — | — | — |
NCT04828486CT.gov Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer | — | Completed | — | — | — |
NCT04787042CT.gov Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | — | Recruiting | — | — | — |
NCT04798781CT.gov Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT04442581CT.gov Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | — | Terminated | — | — | — |
NCT04740307CT.gov Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) | — | Completed | — | — | — |
NCT04696055CT.gov Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors | — | Completed | — | — | — |
NCT04660929CT.gov CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | — | Unknown | — | — | — |
NCT04114136CT.gov Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | — | Recruiting | — | — | — |
NCT04425226CT.gov Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant | — | Unknown | — | — | — |
NCT04222972CT.gov A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT04483778CT.gov B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | — | Active Not Recruiting | — | — | — |
NCT04246177CT.gov Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | — | Completed | — | — | — |
NCT04374877CT.gov Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04251117CT.gov GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC | — | Active Not Recruiting | — | — | — |
NCT04244552CT.gov A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | — | Terminated | — | — | — |
NCT04187872CT.gov LITT and Pembrolizumab in Recurrent Brain Metastasis | — | Terminated | — | — | — |
NCT04224480CT.gov Longitudinal Immune-phenotyping of HCC Following MK-3475 | — | Unknown | — | — | — |
NCT04099277CT.gov A Study of LY3435151 in Participants With Solid Tumors | — | Terminated | — | — | — |
NCT04060342CT.gov GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | — | Terminated | — | — | — |
NCT04234113CT.gov Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT03939975CT.gov Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC | — | Completed | — | — | — |
NCT03849469CT.gov A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | — | Completed | — | — | — |
NCT03867084CT.gov Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) | — | Completed | — | — | — |
NCT03753659CT.gov IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03713593CT.gov Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) | — | Completed | — | — | — |
NCT03836352CT.gov Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03755739CT.gov Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT03511222CT.gov Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | — | Terminated | — | — | — |
NCT03781934CT.gov A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | — | Completed | — | — | — |
NCT03695952CT.gov A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03347292CT.gov Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC | — | Completed | — | — | — |
NCT03419481CT.gov Pembrolizumab in Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03519997CT.gov A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03316872CT.gov Study of Pembrolizumab and Radiotherapy in Liver Cancer | — | Terminated | — | — | — |
NCT03397654CT.gov Study of Pembrolizumab Following TACE in Primary Liver Carcinoma | — | Completed | — | — | — |
NCT04627012CT.gov Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT03163992CT.gov Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib | — | Completed | — | — | — |
NCT03211416CT.gov Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer | — | Completed | — | — | — |
NCT03337841CT.gov Pembrolizumab as Neoadjuvant Treatment in HCC | — | Unknown | — | — | — |
NCT03062358CT.gov Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394) | — | Completed | — | — | — |
NCT03099564CT.gov Pembrolizumab Plus Y90 Radioembolization in HCC Subjects | — | Unknown | — | — | — |
NCT03006926CT.gov A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02940496CT.gov Pembrolizumab (MK-3475) in Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02432963CT.gov Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | — | Active Not Recruiting | — | — | — |
NCT02702414CT.gov Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | — | Completed | — | — | — |
NCT02702401CT.gov Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | — | Completed | — | — | — |
NCT02658019CT.gov Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02595866CT.gov Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | — | Completed | — | — | — |
NCT02509507CT.gov Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 | — | Completed | — | — | — |
NCT02293850CT.gov Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Fudan University | P3 | BB · 68 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →